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Summary
Background Rheumatic heart disease accounts for up to 250 000 premature deaths every year worldwide and can be 
regarded as a physical manifestation of poverty and social inequality. We aimed to estimate the prevalence of 
rheumatic heart disease in endemic countries as assessed by diﬀ erent screening modalities and as a function of age. 
Methods We searched Medline, Embase, the Latin American and Caribbean System on Health Sciences Information, 
African Journals Online, and the Cochrane Database of Systematic Reviews for population-based studies published 
between Jan 1, 1993, and June 30, 2014, that reported on prevalence of rheumatic heart disease among children and 
adolescents (≥5 years to <18 years). We assessed prevalence of clinically silent and clinically manifest rheumatic heart 
disease in random eﬀ ects meta-analyses according to screening modality and geographical region. We assessed the 
association between social inequality and rheumatic heart disease with the Gini coeﬃ  cient. We used Poisson 
regression to analyse the eﬀ ect of age on prevalence of rheumatic heart disease and estimated the incidence of 
rheumatic heart disease from prevalence data.
Findings We included 37 populations in the systematic review and meta-analysis. The pooled prevalence of 
rheumatic heart disease detected by cardiac auscultation was 2·9 per 1000 people (95% CI 1·7–5·0) and by 
echocardiography it was 12·9 per 1000 people (8·9–18·6), with substantial heterogeneity between individual reports 
for both screening modalities (I²=99·0% and 94·9%, respectively). We noted an association between social 
inequality expressed by the Gini coeﬃ  cient and prevalence of rheumatic heart disease (p=0·0002). The prevalence 
of clinically silent rheumatic heart disease (21·1 per 1000 people, 95% CI 14·1–31·4) was about seven to eight times 
higher than that of clinically manifest disease (2·7 per 1000 people, 1·6–4·4). Prevalence progressively increased 
with advancing age, from 4·7 per 1000 people (95% CI 0·0–11·2) at age 5 years to 21·0 per 1000 people (6·8–35·1) 
at 16 years. The estimated incidence was 1·6 per 1000 people (0·8–2·3) and remained constant across age categories 
(range 2·5, 95% CI 1·3–3·7 in 5-year-old children to 1·7, 0·0–5·1 in 15-year-old adolescents). We noted no sex-
related diﬀ erences in prevalence (p=0·829).
Interpretation We found a high prevalence of rheumatic heart disease in endemic countries. Although a reduction in 
social inequalities represents the cornerstone of community-based prevention, the importance of early detection of 
silent rheumatic heart disease remains to be further assessed.
Funding UBS Optimus Foundation.
Copyright © Rothenbühler et al. Open Access article distributed under the terms of CC BY.
Introduction
Rheumatic heart disease ranks among the leading 
causes of non-communicable diseases in low-income 
and middle-income countries and accounts for up to 
250 000 premature deaths every year worldwide.1 Acute 
rheumatic fever and rheumatic heart disease can be 
regarded as physical manifestations of poverty and 
social inequality. Although largely eliminated in high-
income countries, three quarters of children aged 
15 years or younger grow up in parts of the world where 
rheumatic heart disease is endemic.1–3 Rheumatic heart 
disease accounts for the greatest cardiovascular-related 
loss of disability-adjusted life-years among 10–14-year-
olds worldwide4 and continues to be a major public 
health challenge in low-income and middle-income 
countries.
Acute rheumatic fever is caused by an abnormal 
autoimmune response to group A streptococcal 
pharyngitis, which can manifest as arthritis of the large 
joints, aﬀ ect the skin and the brain, and cause cardiac 
inﬂ ammation of the valvular apparatus. Recurrent bouts 
of oligosymptomatic acute rheumatic fever can insidiously 
lead to clinically silent valvular disease through diﬀ erent 
morphological and functional stages, ultimately resulting 
in severe valvular damage and heart failure. Secondary 
antibiotic prophylaxis is the most eﬀ ective therapeutic 
strategy for acute rheumatic fever and rheumatic heart 
disease in low-income and middle-income countries2 and 
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will probably remain so until underlying risk factors—
such as overcrowding, poor hygiene, and limited access to 
health care—are reduced by socioeconomic change. One 
target of the WHO global action plan for the prevention 
and control of non-communicable diseases5 is relative 
reduction of non-communicable disease mortality by 25% 
by the year 2025. Since rheumatic heart disease accounts 
for a substantial proportion of global non-communicable 
diseases, the implementation of comprehensive 
rheumatic heart disease control programmes in low-
income and middle-income countries is a priority.
We aimed to summarise evidence from population-
based observational studies of rheumatic heart disease 
among children and adolescents from endemic countries 
and to identify knowledge gaps. Speciﬁ cally, we aimed to 
assess the eﬀ ect of diﬀ erent screening modalities on 
estimated prevalence.
Methods
Search strategy and selection criteria
We searched Medline, Embase, the Latin-American and 
Caribbean System on Health Sciences Information, 
African Journals Online, and the Cochrane Database of 
Systematic Reviews on July 22, 2014, for population-
based studies on rheumatic heart disease published in 
English, French, Spanish, Dutch, or Portuguese between 
Jan 1, 1993, and June 30, 2014. We restricted the search 
period to the past 20 years, to be representative of the 
present prevalence of rheumatic heart disease. The 
search protocol is shown in the appendix. Inclusion 
criteria were a population-based study design; a sample 
size of at least 500 individuals; inclusion of children at 
least 5 years old and adolescents younger than 18 years; 
and reporting on prevalence of rheumatic heart disease. 
We excluded studies primarily reporting on streptococcal 
infections, acute rheumatic fever, or results after 
intervention or surgery for rheumatic heart disease. Two 
authors (MR and TP) screened all titles and abstracts, 
reviewed full-text articles, and assessed their eligibility 
for inclusion. Disagreements between the two reviewers 
were resolved by discussion; a ﬁ nal decision was reached 
after mutual agreement between the two reviewers or 
was made by a third author (SS).
Data extraction
All data were independently extracted by two reviewers. 
Discrepancies in data extraction were resolved by mutual 
consensus. In addition to the extraction of socio-
demographic characteristics and prevalence ﬁ ndings, we 
assessed methodological aspects of the included studies, 
such as sampling strategy, speciﬁ cation of the sampling 
frame, and screening protocol (eg, independent 
conﬁ rmation and masking).
We diﬀ erentiated between clinically manifest and 
clinically silent rheumatic heart disease. We deﬁ ned 
clinically manifest rheumatic heart disease as the presence 
of a heart murmur on cardiac auscultation that was 
consistent with echocardiographic evidence of rheumatic 
heart disease. Clinically silent rheumatic heart disease was 
deﬁ ned by pathological regurgitation or mitral stenosis, or 
the detection of morphological changes, or both, consistent 
with rheumatic heart disease in the absence of a heart 
murmur. The prevalence of rheumatic heart disease was 
deﬁ ned as the total burden of valvular lesions consistent 
with rheumatic heart disease in a speciﬁ ed population. 
The incidence of rheumatic heart disease is deﬁ ned as the 
number of new cases diagnosed with rheumatic heart 
disease in a speciﬁ ed population and time period, 
irrespective of the presence or absence of signs or 
symptoms of acute rheumatic fever and must not be 
misinterpreted as the occurrence of new episodes of acute 
rheumatic fever, rather than rheumatic heart disease.
Statistical analysis
We compared the extracted data by meta-analysis in Stata 
version 13.1 (StataCorp, College Station, TX, USA) with 
the metan6 and metareg7 commands. We pooled logit 
transformed prevalence estimates using a random-
eﬀ ects model. Estimates were back transformed and 
expressed as conventional prevalence; therefore, 95% CIs 
are asymmetrical throughout. To account for hetero-
geneity due to the screening method (auscultation vs 
echocardiography) and the regional context, we estimated 
the I² summary statistics and report both the conﬁ dence 
and prediction intervals by subgroups. According to 
Higgins and colleagues,8 I² values can be distinguished 
between low (25%), moderate (50%), and high (75%). 
The prediction intervals are calculated taking into 
account the between-study variance τ².6
We assessed the association between social inequality 
and rheumatic heart disease in a scatter plot of the Gini 
coeﬃ  cient of the country and year in which the reported 
screening took place. The Gini coeﬃ  cient measures the 
income distribution within a society on a scale of 0–1, 
where 0 represents perfect equality of distribution of 
income and 1 perfect inequality. A higher Gini coeﬃ  cient 
is therefore equivalent to higher social inequality.9 The 
data for the Gini index were extracted from a World Bank 
database.10 The Gini coeﬃ  cient does not show socio-
economic disparities between ethnic communities 
within one country. We used Poisson regression to 
estimate the prevalence of rheumatic heart disease 
according to social inequality and report both unadjusted 
coeﬃ  cients and coeﬃ  cients adjusted for continent and 
screening methods.
In a sensitivity analysis, we measured the prevalence of 
rheumatic heat disease in school-based and community-
based populations by meta-regression, with the 
diﬀ erence in prevalence assessed by a two-sided Z test. 
We used data from studies that reported prevalence by 
age groups to estimate prevalence of rheumatic heart 
disease as a function of age. We ﬁ rst estimated prevalence 
by age for each study separately. For studies that reported 
prevalence for two age groups, we applied a Poisson 
See Online for appendix
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regression model, and for those with more than two 
age groups, we used fractional polynomial Poisson 
regression. The estimated prevalence per age category 
within each study was then estimated across studies.
Since no direct estimates of incidence were provided in 
individual studies, we estimated the incidence from 
prevalence using the method suggested by Leske and 
colleagues.11 We estimated the overall incidence of 
rheumatic heart disease using the estimated prevalence 
per age category in two steps, as was done for the 
estimation of the prevalence by age: ﬁ rst within each 
study separately and then between the studies by meta-
regression. We ﬁ rst estimated incidence by age within 
each study using the method suggested by Leske and 
colleagues11 and then estimated incidence across all 
studies by meta-regression. We estimated the incidence 
using the three underlying assumptions of Leske and 
colleagues.11 First, we assumed that the mortality rate was 
constant and did not depend on age. Second, we assumed 
that the mortality rate among children under 16 years 
was independent of rheumatic heart disease. Third, we 
assumed that there was no disease regression. We 
ignored possible enrolment in secondary prevention 
programmes or any natural healing and assumed that 
the disease progression was constant over time. The 
underlying assumptions represent a simpliﬁ cation of the 
complex physiopathology of rheumatic heart disease. 
The appendix includes further information regarding the 
estimation of the incidence. Finally, we estimated the 
prevalence of silent and manifest rheumatic heart disease 
using data from studies that reported prevalence 
according to both screening modalities and that used the 
WHO deﬁ nition of rheumatic heart disease, which 
diﬀ erentiates between silent (ie, possible) and manifest 
(ie, probable and deﬁ nite) rheumatic heart disease.2
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. MR and TP had full access to all the data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
We identiﬁ ed 2928 publications, 85 of which were 
potentially eligible (ﬁ gure 1). 33 articles describing 
37 populations met the inclusion criteria and were included 
in the systematic review and meta-analysis;12–44  four of the 
publications included data from two population-based 
studies each.25,28,31,37 The appendix includes a summary of 
the methodological characteristics reported in the included 
studies. The sampling frame was speciﬁ ed in 28 (76%) 
populations and the sampling strategy was speciﬁ ed in 
27 (73%). The primary sampling unit was schools in 
34 (92%) populations and communities in three (8%).
In studies using cardiac auscultation as the primary 
means for screening, various reasons for referral were 
used. In some studies, children with any heart murmur 
(functional or pathological) were referred for 
echocardiographic examination, whereas in others 
children with pathological murmurs only were referred. 
Diﬀ erent criteria for echocardiographic detection of 
rheumatic heart disease were used across studies. In 
most studies rheumatic heart disease was only 
diagnosed if both pathological regurgitation of left-sided 
valves and morphological features were present, 
whereas in others, the diagnosis was made if isolated 
pathological regurgitation or isolated morphological 
features were present. Methodological characteristics 
and sample sizes of the individual studies are shown in 
2928 titles recorded
 33 in African Journals Online
 346 in Cochrane
 1159 in PubMed
 1213 in Embase
 177 in Latin-American and Caribbean 
  System on Health Sciences Information
1607 excluded (1447 in agreement and 160 after 
 discussion)
 31 guidelines
 81 interventions for RHD
 201 not RHD
 189 case reports
 181 reviews
 924 not population-based studies
53 excluded (34 in agreement and 19 after 
 discussion)
 9 not RHD
 11 no prevalence rate
 6 duplicated reporting of results
 14 not children or adolescents
 13 not population-based studies
1850 titles and abstracts screened
243 titles and abstracts preliminarily included 
 (154 in agreement and 89 after discussion)
158 excluded because date of publication before 
 Jan 1, 1993
85 full-text articles assessed for eligibility
1 publication retained from references for 
 meta-analysis*
33 publications included in meta-analysis 
 (31 in agreement and 2 after discussion)
 1078 duplicates excluded
Figure 1: Flow diagram of manuscript selection
RHD=rheumatic heart disease. *Identiﬁ ed from the reference list from one article included in the meta-analysis 
during full-text assessment for eligibility.
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the appendix, as are the clinical deﬁ nition and 
echocardiographic criteria applied for case detection of 
rheumatic heart disease.
Among the 37 populations, 17 were from Asia, nine 
Africa, seven Oceania, three Latin America, and one 
Europe. The appendix summarises baseline characteristics 
Country Years of
screening
Asia
Vashistha et al43
Ahmed et al14
Agarwal et al13
Thakur et al42
Regmi and Pandey36
Al–Munibari et al15
Kaul et al26
Jose et al24
Marijon et al28
Sadiq et al38
Misra et al29
Periwal et al35
Ba–Saddik et al18
Gul et al23
Bhaya et al20
Negi et al30
Saxena et al40
Pooled
I2=99·4%, τ2=3·2 (95% PI 0·0–117·1)
Africa
Abdel–Moula et al12
Anabwani and Bonhoeﬀer16
Oli and Porteous33
Longo–Mbenza et al27
Marijon et al28
Beaton et al19
Kane et al (5–15 years)25
Kane et al (16–18 years)25
Sadoh et al39
Pooled
I2=81·8%, τ2=0·3 (95% PI 1·3–16·5)
Latin America
Nordet et al31
Nordet et al31
Paar et al34
Pooled
I2=94·2%, τ2=1·6 (95% PI 0·0–1000·0) 
Oceania
Carapetis et al21
Steer et al41
Webb et al44
Pooled
I2=97·4%, τ2=1·2 (95% PI 0·0–1000·0)
Europe
Olgunturk et al32
Overall
I2=99·0%, τ2=2·4 (95% PI 0·1–69·1)
India
Bangladesh
India
India
Nepal
Yemen
India
India
Cambodia
Pakistan
India
India
Yemen
Pakistan
India
India
India
Egypt
Kenya
Ethiopia
Congo
Mozambique
Uganda
Senegal
Senegal
Nigeria
Cuba
Cuba
Nicaragua
Tonga
Fiji
New Zealand
Turkey
1989–90
1991
1991–92
1992–93
1997
1997–98
1999–2000
2001–02
2001–02
2001–02
2003–06
2004
2004–05
2006–07
2007–08
2007–08
2008–10
1993–94
1994
1995
1996
2005
2010
2010
2010
2011–12
1985
1996
2006–09
2003–04
2006
2007–08
1995
 1·4 (0·8–2·5)
 1·4 (0·7–2·7)
 5·2 (2·6–10·3)
 3·0 (2·2–4·0)
 1·3 (0·6–2·8)
 3·6 (2·3–5·7)
 5·1 (3·3–7·8)
 0·7 (0·6–0·8)
 2·2 (1·1–4·3)
 21·9 (20·1–23·8)
 0·5 (0·4–0·7)
 16·7 (12·6–21·9)
 36·5 (32·0–41·6)
 1·7 (0·5–5·2)
 0·9 (0·1–6·7)
 0·6 (0·3–1·1)
 0·8 (0·3–1·9)
 2·6 (1·1–6·1)
 6·2 (4·4–8·7)
 2·7 (0·9–8·3)
 6·4 (5·0–8·2)
 12·2 (9·4–15·7)
 2·3 (1·0–5·5)
 5·1 (3·5–7·6)
 1·8 (0·4–7·1)
 1·1 (0·2–7·9)
 0·6 (0·1–4·0)
 4·6 (3·0–7·0)
 2·3 (1·3–3·9)
 0·2 (0·1–0·5)
 4·1 (2·4–7·1)
 1·3 (0·3–5·9)
 38·4 (33·3–44·2)
 8·4 (5·8–12·0)
 7·0 (3·5–13·9)
 13·5 (3·8–46·2)
 0·7 (0·2–2·3)
 2·9 (1·7–5·0)
0 10 403020
Prevalence per
1000 people (95% CI)
Figure 2: Prevalence of 
rheumatic heart disease in 
studies in which patients 
were screened using cardiac 
auscultation
Prevealence estimated from 
logit transformed data; 
therefore, 95% CIs are 
asymmetrical. PI=prediction 
interval.
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of the included studies. The mean age of the study 
population, as reported in 20 studies, was 11 years (SD 2), 
and the median proportion of boys, as reported in 
27 studies, was 53% (IQR 49–56). Valvular involvement of 
the detected cases of rheumatic heart disease was reported 
in 27 studies. A mean of 65% (SD 31) of children and 
adolescents had mitral regurgitation, 21% (SD 18) had 
aortic regurgitation, and 15% (SD 22) had mitral stenosis.
Active surveillance with echocardiography was done 
in 14 studies, whereas in 23 studies individuals were 
screened for the presence of rheumatic heart disease by 
cardiac auscultation primarily, and eventually referred 
for further assessment only in case of a cardiac 
murmur. In ten studies, screening was done using both 
cardiac auscultation and echnocardiography. Findings 
were conﬁ rmed independently in 29 studies. The 
pooled prevalence of rheumatic heart disease detected 
by cardiac auscultation was 2·9 per 1000 people (95% CI 
1·7–5·0; ﬁ gure 2) and by echocardiography it was 
12·9 per 1000 people (8·9–18·6; ﬁ gure 3). The 
heterogeneity of reported prevalence in diﬀ erent 
studies from diﬀ erent continents was high for both 
studies in which rheumatic heart disease was detected 
by cardiac auscultation (I²=99·0%; ﬁ gure 2) and in 
those in which it was detected by echocardiography 
(I²=94·9%; ﬁ gure 3). In the sensitivity analysis, we 
found no signiﬁ cant interaction between prevalence in 
school-based and community-based active surveillance 
programmes (p=0·200).
The prevalence of clinically silent rheumatic heart 
disease (21·1 per 1000 people, 95% CI 14·1–31·4) was 
about seven to eight times higher than that of clinically 
manifest disease (2·7 per 1000 people, 1·6–4·4; ﬁ gure 4). 
The prevalence of rheumatic heart disease by age groups 
was provided in 15 publications.17–19,21,25–27,30,36,37,39–43 The 
prevalence of rheumatic heart disease progressively 
increased with advancing age, from 4·7 per 1000 people 
(95% CI 0·0–11·2) at age 5 years, to 21·0 per 1000 people 
(6·8–35·1) at 16 years (ﬁ gure 5). Prevalence and incidence 
per study as a function of age are summarised in the 
appendix. On the basis of estimates of prevalence per age 
category, we estimated an overall incidence rate of 1·6 
per 1000 people (95% CI 0·8–2·3), which remained 
constant across age categories (range 2·5, 95% CI 
Country Years of
screening
Asia
Marijon et al28
Bhaya et al20
Saxena et al40
Pooled
I2=94·3%, τ2=0·2 (95% PI 0·0–962·3)
Africa
Anabwani and Bonhoeﬀer16
Marijon et al28
Beaton et al19
Kane et al (5–15 years)25
Kane et al (16–18 years)25
Pooled
I2=94·9%, τ2=1·2 (95% PI 0·2–278·9)
Oceania
Webb et al44
Baroux et al17
Roberts et al (high-risk cohort)37
Roberts et al (low-risk cohort)37
Cramp et al22
Pooled
I2=94·4%, τ2=0·4 (95% PI 1·4–123·5)
Latin America
Paar et al34
Overall
I2=94·9%, τ2=0·4 (95% PI 2·9–55·7)
Cambodia
India
India
Kenya
Mozambique
Uganda
Senegal
Senegal
New Zealand
Australia
New Caledonia
Australia
New Zealand
Nicaragua
2001–02
2007–08
2008–10
1994
2005
2010
2010
2010
2007–08
2008–10
2008–10
2008–10
2009
2006–09
 21·5 (17·3–26·7)
 51·0 (39·2–66·0)
 20·4 (17·2–24·2)
 28·0 (16·6–49·9)
 2·7 (0·9–8·3)
 30·4 (24·0–38·5)
 5·1 (3·5–7·6)
 5·4 (2·4–11·9)
 10·1 (5·3–19·4)
 7·9 (2·9–21·4)
 23·6 (16·3–34·3)
 8·9 (7·4–10·7)
 25·3 (20·9–30·7)
 4·7 (2·0–11·4)
 16·1 (8·9–28·7)
 14·0 (7·7–25·5)
 4·1 (2·4–7·1)
 12·9 (8·9–18·6)
0 10 6050403020
Prevalence per
1000 people (95% CI)
Figure 3: Prevalence of rheumatic heart disease in studies in which patients were screened using echocardiography
Prevalence estimated from logit transformed data; therefore, 95% CIs are asymmetrical. PI=prediction interval. 
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1·3–3·7 in 5-year-old children to 1·7, 0·0–5·1 in 15-year-
old adolescents).
The prevalence of rheumatic heart disease by sex was 
provided in 14 publications (38%).13,17–19,26,27,33,35,36,38,40–43 There 
were no signiﬁ cant diﬀ erences in the overall prevalence 
between girls (10·1 per 1000 people, 95% CI 6·6–13·5) 
and boys (9·5 per 1000 people, 6·0–13·1; p=0·829). The 
prevalence in those who were screened by auscultation 
was 7·8 per 1000 people (95% CI 2·9–12·8) among boys 
and 7·7 per 1000 people (3·3–12·2) among girls (p=0·977). 
Screening by echocardiography resulted in a prevalence of 
13·9 per 1000 people (95% CI 8·3–19·5) among girls and 
12·3 per 1000 people (7·2–17·4) among boys (p=0·662).
Prevalence of rheumatic heart disease varied by social 
inequality measured by the Gini coeﬃ  cient (p=0·0002; 
ﬁ gure 6). An increment of 0·1 of the Gini coeﬃ  cient was 
associated with an increase in prevalence by a factor of 
1·4 (95% CI 1·2–1·6). The association between Gini 
coeﬃ  cient and prevalence of rheumatic heart disease 
persisted after adjusting for continent (p<0·0001) and 
screening method (p=0·049).
Discussion
In this systematic review and meta-analysis of population-
based studies of endemic regions across Oceania, Asia, 
Africa, Latin America, and Europe we noted a high 
prevalence of rheumatic heart disease, with substantial 
heterogeneity between ﬁ ndings. Prevalence of rheumatic 
heart disease progressively increased between the ages of 
5 years and 16 years, with a stable incidence rate, and that 
Country Years of
screening
Clinically manifest rheumatic heart disease
Marijon et al28
Marijon et al28
Bhaya et al20
Paar et al34
Webb et al44
Saxena et al40
Beaton et al19
Kane et al (5–15 years)25
Kane et al (16–18 years)25
Pooled
I2=93·2%, τ2=0·33 (95% PI 0·1–68·5)
Clinically silent rheumatic heart disease
Marijon et al28
Marijon et al28
Bhaya et al20
Paar et al34
Webb et al44
Saxena et al40
Beaton et al19
Kane et al (5–15 years)25
Kane et al (16–18 years)25
Pooled
I2=94·5%, τ2=0·35 (95% PI 5·5–82·4)
Z value: –4·02; p=0·0001
Cambodia
Mozambique
India
Nicaragua
New Zealand
India
Uganda
Senegal
Senegal
Cambodia
Mozambique
India
Nicaragua
New Zealand
India
Uganda
Senegal
Senegal
2001–02
2005
2007–08
2006–09
2007–08
2008–10
2010
2010
2010
2001–02
2005
2007–08
2006–09
2007–08
2008–10
2010
2010
2010
 2·2 (1·1–4·3)
 2·3 (1·0–5·5)
 0·9 (0·1–6·7)
 4·1 (2·4–7·1)
 7·0 (3·5–13·9)
 0·8 (0·3–1·9)
 5·1 (3·5–7·6)
 1·8 (0·4–7·1)
 1·1 (0·2–7·9)
 2·7 (1·6–4·4)
 
19·3 (15·3–24·3)
 28·1 (21·9–36·0)
 50·1 (38·4–64·9)
 43·5 (36·9–51·2)
 44·7 (34·1–58·3)
 19·6 (16·5–23·4)
 9·7 (7·3–12·8)
 3·6 (1·3–9·5)
 9·0 (4·5–17·9)
 21·1 (14·1–31·4)
0 10 60 7040 503020
Prevalence per
1000 people (95% CI)
Figure 4: Prevalence of clinically silent and clinically manifest rheumatic heart disease
Prevalence in studies in which patients were screened using echocardiography. Prevalence estimated from logit transformed data; therefore, 95% CIs are asymmetrical. 
This analysis only included studies that reported prevalence of both silent and manifest rheumatic heart disease. PI=prediction interval.
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Figure 5: Prevalence and incidence of rheumatic heart disease according to age
Dashed lines are 95% CIs. 95% CIs have been truncated to zero in case of negative 
values. This analysis only included studies that reported prevalence by age groups.
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of clinically silent rheumatic heart disease was seven to 
eight times higher than that of clinically manifest 
disease. Additionally, diﬀ erences in estimated prevalence 
represented economic disparities and were associated 
with social inequality.
Reported prevalence of rheumatic heart disease among 
children and adolescents in endemic regions of the world 
ranged up to 5%, with substantial heterogeneity between 
populations. The diﬀ erences in reported prevalence 
seem to represent true disparities in disease burden and 
are aﬀ ected by methodological discrepancies in the 
undertaking of the studies, diﬀ erent methods and 
deﬁ nitions applied for case detection, and the timeline of 
included data.
Several of the included studies had limited methodological 
strength and statistical precision at diﬀ erent levels. Most 
studies were underpowered to assess prevalence with 
adequate accuracy because of a small number of selected 
schools of communities or a small number of participants, 
or both. The setting (urban or rural) was not speciﬁ ed in 
most studies, which might introduce a latent bias into our 
prevalence estimates. Compared with urban areas, the 
prevalence of rheumatic heart disease seems to be higher 
in rural settings.28,34 A quarter of studies omitted to 
adequately report the sampling strategy of the study 
population, which might further aﬀ ect the reproducibility 
of the presented ﬁ ndings. Studies with sampling on the 
basis of school lists might underestimate the true burden 
of disease since school attendance is associated with 
socioeconomic status, a major risk factor for rheumatic 
heart disease.37 However, in a sensitivity analysis, we 
found no signiﬁ cant interaction between prevalence in 
school-based and community-based active surveillance 
programmes. In a subset of studies, the diﬀ erence between 
the sample of eligible pupils and the number of eﬀ ectively 
screened students because of missing consent or failure to 
re-examine absentees from school in a repeat screening 
visit might have contributed to an underestimation of the 
actual burden of disease.
Diﬀ erences in deﬁ nitions and criteria for the diagnosis of 
rheumatic heart disease,45,46 training of the examiner,21 and 
utility of handheld or standard portable devices47 have been 
outlined previously. Cardiac auscultation is an ineﬀ ective 
method of screening for rheumatic heart disease, regardless 
of the expertise of the auscultator.48 Diﬀ erentiation between 
innocent and suspicious or pathological murmurs can be 
challenging. In a staged screening protocol, sensitivity of 
auscultation to detect any cardiac murmur was higher 
when done by medical students than by paediatricians 
(96·4% vs 80·0%), although this came at the expense of 
lower speciﬁ city (1·3% vs 20·6%). In a second stage, 
classiﬁ cation of the previously detected murmurs into 
innocent or suspicious murmurs by a trained paediatrician 
increased the speciﬁ city to detect rheumatic heart disease 
from 20·6% to 65·1%, but reduced sensitivity from 80·0% 
to 46·4%.21 A high level of suspicion for any heart murmur 
or a more rigorous referral strategy for echocardiographic 
conﬁ rmation might therefore have  substantially aﬀ ected 
documented prevalence in studies in which cardiac 
auscultation was used as the primary screening method. 
Accordingly, of the four studies reporting the highest 
prevalence of rheumatic heart disease by screening 
auscultation,18,21,35,38 ﬁ ndings from three suggested that 
children and adolescents with any heart murmur 
(functional and pathological) were referred for 
echocardiography.21,35,38 Similarly, prevalence of rheumatic 
heart disease identiﬁ ed on echocardiography might vary 
according to the diagnostic criteria used. The combined 
use of doppler-based and morphology-based criteria (any 
amount of valvular regurgitation noted in at least two 
planes associated with at least two of the following 
morphological signs: leaﬂ et restriction, subvalvular 
thickening, or valvular thickening) had a three to four times 
higher rate of detection of subclinical rheumatic heart 
disease compared with the exclusive use of doppler-based 
criteria (regurgitant jet >1 cm in length, regurgitant jet in at 
least two planes, mosaic colour jet with a peak velocity 
>2·5 m/s, and persisting jet throughout systole or diastole) 
in a cohort of 2170 children screened in Mozambique.49 
Although in most studies pathological regurgitation of left-
sided valves in combination with morphological features 
was deemed diagnostic for rheumatic heart disease, in 
other studies, isolated pathological regurgitation or isolated 
morphological features was suﬃ  cient for case detection. 
Moreover, interobserver reliability of screening ﬁ ndings 
was assessed in only 22% of studies.
Echocardiography for active surveillance has important 
beneﬁ ts above and beyond the increased sensitivity and 
speciﬁ city compared with cardiac auscultation. The 
process involves common deﬁ nitions and criteria for 
Figure 6: Prevalence of rheumatic heart disease according to social inequality
The size of the bubbles corresponds to the sample size of the reported study. The red line represents the estimated 
prevalence of rheumatic heart disease according to income distribution, with the 95% CI in grey.
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diagnosis, independent and masked conﬁ rmatory 
assessments, and structured documentation. However, 
whereas in most studies in our analysis independent 
conﬁ rmation of preliminary ﬁ ndings from on-site 
screening was done by a second assessor masked or 
unmasked to the suspected diagnosis, not all studies 
reported conﬁ rmation of their ﬁ ndings.
Prevalence of rheumatic heart disease has declined 
over the past few decades.50 A decline in disease burden 
might have contributed to the noted heterogeneity in 
reported prevalence, since the retained studies had been 
done over a timespan of over 20 years. 
Consistent with ﬁ ndings from previous reports, we noted 
a continuous increase in the prevalence of rheumatic heart 
disease with advancing age;19,25 however, this prevalence 
estimate must be interpreted with caution. The age range 
selected for active surveillance was determined by years of 
school attendance in most studies, and data on prevalence 
of rheumatic heart disease among adolescents in their late 
teens are scarce. Data from Senegal suggested a numerically 
higher prevalence of rheumatic heart disease among 
adolescents aged 16–18 years (10·1 per 1000 people, 95% CI 
4·6–19·2) compared with children aged 5–15 years (5·4 per 
1000 people, 2·0–11·7) and a numerically higher amount of 
advanced disease in adolescents (89%) than in children 
(33%; p=0·08).25 These results were in line with those from 
a community-based screening programme in Pakistan.51
Corresponding with the steady increase in prevalence 
with advancing age, we estimated a constant incidence 
rate across age categories between 5 years and 15 years. 
The incidence estimate has to be interpreted in view 
of several limitations. First, any imprecision in 
approximated prevalence by age would directly transfer 
to the estimation of incidence. Second, the model used 
for the estimation of incidence did not account for 
mortality secondary to rheumatic heart disease and 
assumed a constant mortality rate independent of age. 
Finally, the model did not take into consideration the 
regression of disease that has been noted in several 
studies.20,34,40,52 Notwithstanding, the estimated incidence 
of 1·6 per 1000 people is consistent with the reported 
incidence in Northern Territory, Australia.53
Several studies have reported a higher prevalence of 
rheumatic heart disease among women than men.13,51,54–58 
In contrast to ﬁ ndings from two previous community-
based studies among predominantly young adults,13,51 we 
did not document sex-related diﬀ erences in prevalence of 
rheumatic heart disease in children in the present 
analysis of primarily school-based observational studies. 
A diﬀ erence in sex-related prevalence ratios between 
children and adults might be explained by under-
schooling of girls or a greater cumulative exposure to 
β-haemolytic streptococci of young, child-rearing 
mothers compared with men. Alternatively, diﬀ erences 
in the diagnostic capacity of diﬀ erent screening 
modalities between females and males might contribute 
to the diﬀ erence in sex-speciﬁ c prevalence among 
children and adults. Since data on rheumatic heart 
disease among adults typically refers to clinically 
manifest disease as detected by auscultation, rather than 
to subclinical disease, a higher rate of echocardiographic 
false-negative ﬁ ndings among girls compared with boys 
might explain the noted sex diﬀ erence as much as a 
higher rate of false-negative ﬁ ndings during auscultation 
in men compared with women. Because of limited data, 
we could not analyse whether there were diﬀ erences in 
prevalence according to sex and age or investigate the 
relation between sex and the primary sampling unit 
(school-based versus community-based).
We noted a prevalence of clinically silent rheumatic 
heart disease that was seven to eight times higher than 
that of clinically manifest disease. In the absence of a 
history of acute rheumatic fever, a large proportion of 
silent cases is representative of latent disease, detected 
only by active echocardiographic surveillance. The low 
sensitivity of cardiac auscultation for detection of 
rheumatic heart disease and the resulting under-
estimation of the disease burden have been highlighted in 
several studies.19,20,25,28,34,40 However, the natural course and 
the prognostic eﬀ ect of latent rheumatic heart disease 
need to be further elucidated. Longitudinal studies of 
children diagnosed with rheumatic heart disease in 
observational studies are limited by the small number of 
patients, high proportion of children lost to follow-up, and 
short duration of follow-up to a maximum of 2 years. 
Regression was noted in about a third of children with 
early stages of disease and was predominantly associated 
with a reduction of mitral regurgitation, whereas 
morphological changes were less likely to improve;34,40,59,60 
disease progression occurred in 5–15% of children.34,40,59 
The identiﬁ cation of children at risk of disease progression 
remains challenging. Advanced stages of disease and 
valvular morphological abnormalities, young age at initial 
diagnosis, and high anti-streptolysin O titres are associated 
with an increased risk of disease progression.59,60 Timely 
implementation of secondary prevention strategies for 
silent rheumatic heart disease can prevent or slow the 
progression of valvular lesions.59–61
Diﬀ erences in the estimated prevalence are suggestive 
of economic disparities and are associated with social 
inequality. A higher Gini index—a measure of the extent 
to which income and expenditures are distributed within 
a population—is associated with a higher prevalence of 
rheumatic heart disease. However, heterogeneity across 
neighbouring geographical regions with similar socio-
economic backgrounds suggests under-reporting of the 
disease and might result from competition for limited 
resources with other non-communicable diseases in 
many low-income and middle-income countries. 
Rheumatic heart disease causes the highest number of 
disability-adjusted life-years of all listed cardiovascular 
diseases among 10–14-year-olds (516·6 per 100 000 people, 
95% CI 425·3–647·0) and the second highest number 
among children aged 5–9 years (362·0, 294·6–462·0).4 
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These ﬁ gures underscore the fact that rheumatic heart 
disease continues to be a major contributor to loss of 
health among children. Neglect of rheumatic heart 
disease on a governmental level in many low-income 
and middle-income countries translates into under-
representation of rheumatic heart disease in the peer-
reviewed published work.
Prevention policies and institutionalised programmes 
are paramount for the control of rheumatic heart disease 
in endemic countries. In 2005, the Drakensberg 
Declaration62 issued a call for the development of national 
programmes in Africa, focusing on raising awareness, 
surveillance, advocacy, and prevention. Community 
awareness and targeted education of major stakeholders 
play an integral part in the consistent implementation of 
dedicated prevention programmes. At the same time, 
integration of rheumatic heart disease into national non-
communicable disease programmes with active disease 
surveillance is essential. Collaborative eﬀ orts have 
resulted in the Mosi-o-Tunya call to action,63,64 which 
outlines a strategic roadmap for addressing the 
challenges of rheumatic heart disease in Africa.
The global targets of WHO oﬀ er a unique opportunity 
to return rheumatic heart disease to the clinical and 
scientiﬁ c mainstream.65,66 The ambitious targets set out 
in the WHO global action plan,5 namely to reduce 
premature mortality related to non-communicable 
diseases by 25% by the year 2025, would be more 
achievable if a common approach was adopted and 
awareness of rheumatic heart disease raised by high-
quality and congruent research methodology. There are 
no guidelines on the undertaking of active surveillance 
for rheumatic heart disease. Although academic 
publications about rheumatic heart disease have 
substantially decreased since the 1970s, the number of 
published research articles has steadily increased since 
the beginning of the 21st century. This increase in 
scientiﬁ c attention might have an eﬀ ect on research 
funding and might lead to the transformation 
of knowledge into tangible action consisting of 
commensurate funding for the establishment of national 
control programmes for rheumatic heart disease and 
equitable access to primary and secondary preventative 
treatment.
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